Access to hematopoietic stem cell transplant for patients with sickle cell anemia

Emily Riehm Meier, Theodore Samuel Johnson, Kerice Pinkney, Maria C. Velez, Naynesh Kamani, Isaac Odame

Research output: Contribution to journalReview article

Abstract

Hematopoietic stem cell transplantation (HSCT) is a curative therapy for patients with phenotypically severe sickle cell anemia, and survival rates following matched-sibling HSCT are very high. However, despite cure rates much higher than HSCT for malignant diseases, the field has been slow to adopt this treatment modality for sickle cell anemia. This article explores some of the social forces that may contribute to this dichotomy.

LanguageEnglish (US)
Article numbere27105
JournalPediatric Blood and Cancer
Volume65
Issue number9
DOIs
StatePublished - Sep 1 2018

Fingerprint

Hematopoietic Stem Cell Transplantation
Sickle Cell Anemia
Hematopoietic Stem Cells
Transplants
Siblings
Cell Survival
Survival Rate
Therapeutics

Keywords

  • diversity
  • healthcare disparities
  • hematopoietic stem cell transplant
  • hydroxyurea
  • sickle cell anemia

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Cite this

Access to hematopoietic stem cell transplant for patients with sickle cell anemia. / Meier, Emily Riehm; Johnson, Theodore Samuel; Pinkney, Kerice; Velez, Maria C.; Kamani, Naynesh; Odame, Isaac.

In: Pediatric Blood and Cancer, Vol. 65, No. 9, e27105, 01.09.2018.

Research output: Contribution to journalReview article

Meier, Emily Riehm ; Johnson, Theodore Samuel ; Pinkney, Kerice ; Velez, Maria C. ; Kamani, Naynesh ; Odame, Isaac. / Access to hematopoietic stem cell transplant for patients with sickle cell anemia. In: Pediatric Blood and Cancer. 2018 ; Vol. 65, No. 9.
@article{3a86a4b575284504974e5b6a1b90a57a,
title = "Access to hematopoietic stem cell transplant for patients with sickle cell anemia",
abstract = "Hematopoietic stem cell transplantation (HSCT) is a curative therapy for patients with phenotypically severe sickle cell anemia, and survival rates following matched-sibling HSCT are very high. However, despite cure rates much higher than HSCT for malignant diseases, the field has been slow to adopt this treatment modality for sickle cell anemia. This article explores some of the social forces that may contribute to this dichotomy.",
keywords = "diversity, healthcare disparities, hematopoietic stem cell transplant, hydroxyurea, sickle cell anemia",
author = "Meier, {Emily Riehm} and Johnson, {Theodore Samuel} and Kerice Pinkney and Velez, {Maria C.} and Naynesh Kamani and Isaac Odame",
year = "2018",
month = "9",
day = "1",
doi = "10.1002/pbc.27105",
language = "English (US)",
volume = "65",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "9",

}

TY - JOUR

T1 - Access to hematopoietic stem cell transplant for patients with sickle cell anemia

AU - Meier, Emily Riehm

AU - Johnson, Theodore Samuel

AU - Pinkney, Kerice

AU - Velez, Maria C.

AU - Kamani, Naynesh

AU - Odame, Isaac

PY - 2018/9/1

Y1 - 2018/9/1

N2 - Hematopoietic stem cell transplantation (HSCT) is a curative therapy for patients with phenotypically severe sickle cell anemia, and survival rates following matched-sibling HSCT are very high. However, despite cure rates much higher than HSCT for malignant diseases, the field has been slow to adopt this treatment modality for sickle cell anemia. This article explores some of the social forces that may contribute to this dichotomy.

AB - Hematopoietic stem cell transplantation (HSCT) is a curative therapy for patients with phenotypically severe sickle cell anemia, and survival rates following matched-sibling HSCT are very high. However, despite cure rates much higher than HSCT for malignant diseases, the field has been slow to adopt this treatment modality for sickle cell anemia. This article explores some of the social forces that may contribute to this dichotomy.

KW - diversity

KW - healthcare disparities

KW - hematopoietic stem cell transplant

KW - hydroxyurea

KW - sickle cell anemia

UR - http://www.scopus.com/inward/record.url?scp=85046078246&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046078246&partnerID=8YFLogxK

U2 - 10.1002/pbc.27105

DO - 10.1002/pbc.27105

M3 - Review article

VL - 65

JO - Pediatric Blood and Cancer

T2 - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 9

M1 - e27105

ER -